DK0528527T3 - Konjugater - Google Patents

Konjugater

Info

Publication number
DK0528527T3
DK0528527T3 DK92306149T DK92306149T DK0528527T3 DK 0528527 T3 DK0528527 T3 DK 0528527T3 DK 92306149 T DK92306149 T DK 92306149T DK 92306149 T DK92306149 T DK 92306149T DK 0528527 T3 DK0528527 T3 DK 0528527T3
Authority
DK
Denmark
Prior art keywords
antibody
conjugates
toxin
tumours
treating gastrointestinal
Prior art date
Application number
DK92306149T
Other languages
English (en)
Inventor
Andrew Firman Wright
David Charles Blakey
John Edward Fitton
Peter Lind
Leif Lindholm
Jan Holmgren
Original Assignee
Zeneca Ltd
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Pharmacia & Upjohn Ab filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DK0528527T3 publication Critical patent/DK0528527T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92306149T 1991-07-03 1992-07-03 Konjugater DK0528527T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (1)

Publication Number Publication Date
DK0528527T3 true DK0528527T3 (da) 1999-01-18

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92306149T DK0528527T3 (da) 1991-07-03 1992-07-03 Konjugater

Country Status (24)

Country Link
EP (1) EP0528527B1 (da)
JP (1) JP3735379B2 (da)
KR (1) KR100252147B1 (da)
AT (1) ATE164768T1 (da)
AU (1) AU665546B2 (da)
CA (1) CA2073113C (da)
CZ (1) CZ209792A3 (da)
DE (1) DE69225035T2 (da)
DK (1) DK0528527T3 (da)
ES (1) ES2113923T3 (da)
FI (1) FI106928B (da)
GB (2) GB9114399D0 (da)
GR (1) GR3026575T3 (da)
HU (1) HU215243B (da)
IE (1) IE922190A1 (da)
IL (1) IL102399A (da)
MY (1) MY110513A (da)
NO (1) NO308539B1 (da)
NZ (1) NZ243437A (da)
PT (1) PT100660B (da)
SK (1) SK209792A3 (da)
TW (1) TW329425B (da)
ZA (1) ZA924973B (da)
ZW (1) ZW10192A1 (da)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1992001470A1 (en) * 1990-07-20 1992-02-06 Kabi Pharmacia Ab Target specific antibody-superantigen conjugates and their preparation

Also Published As

Publication number Publication date
ES2113923T3 (es) 1998-05-16
JP3735379B2 (ja) 2006-01-18
HU9202219D0 (en) 1992-10-28
AU665546B2 (en) 1996-01-11
IE922190A1 (en) 1993-01-13
CA2073113A1 (en) 1993-01-04
FI923085A0 (fi) 1992-07-03
ZW10192A1 (en) 1993-03-31
ATE164768T1 (de) 1998-04-15
EP0528527B1 (en) 1998-04-08
CA2073113C (en) 2004-09-14
NO922383D0 (no) 1992-06-17
AU1943092A (en) 1993-01-07
SK209792A3 (en) 1994-06-08
NO922383L (no) 1993-01-04
PT100660A (pt) 1993-10-29
GB9212880D0 (en) 1992-07-29
KR100252147B1 (ko) 2000-09-01
EP0528527A2 (en) 1993-02-24
EP0528527A3 (en) 1993-03-17
GR3026575T3 (en) 1998-07-31
GB9114399D0 (en) 1991-08-21
ZA924973B (en) 1993-04-28
IL102399A (en) 2003-05-29
JPH05320065A (ja) 1993-12-03
TW329425B (en) 1998-04-11
HU215243B (hu) 1998-11-30
NZ243437A (en) 1994-10-26
NO308539B1 (no) 2000-09-25
PT100660B (pt) 1999-06-30
HUT67048A (en) 1995-01-30
DE69225035T2 (de) 1998-08-13
MY110513A (en) 1998-07-31
IL102399A0 (en) 1993-01-14
FI106928B (fi) 2001-05-15
KR930001928A (ko) 1993-02-22
CZ209792A3 (en) 1993-01-13
DE69225035D1 (de) 1998-05-14
FI923085A (fi) 1993-01-04

Similar Documents

Publication Publication Date Title
ATE46084T1 (de) Immunotoxin-konjugate.
FI103792B1 (fi) Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja
ATE144523T1 (de) Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen
IL68106A0 (en) Immunoenzymic conjugates,their preparation and medicinal associations of such conjugates with immunotoxins
NO304552B1 (no) Kompleksforbindelser, konjugater, farmas°ytiske preparater inneholdende slike og forbindelser
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
HU9203649D0 (en) Method for producing inclusion compounds of nimesulide with cyclodextrines and pharmaceutical preparatives containing these compounds
DE69225035T2 (de) Konjugate
ATE103972T1 (de) Monoklonale antikoerper gegen anthracycline.
ITMI910660A1 (it) Anticorpi monoclonali come antidoti